Escudier B., Porta C., Bono P., Powles T., Eisen T., Sternberg C.N., Gschwend J.E., De Giorgi U., Parikh O., Hawkins R., Sevin E., Négrier S., Khan S., Diaz J., Redhu S., Mehmud F., Cella D.
Journal of Clinical Oncology 2014 32:14 (1412-1418)
Purpose: Patient-reported outcomes may help inform treatment choice in advanced/metastatic renal cell carcinoma (RCC), particularly between approved targeted therapies with similar efficacy. This double-blind cross-over study evaluated patient preference for pazopanib or sunitinib and the influence of health-related quality of life (HRQoL) and safety factors on their stated preference. Patients and Methods: Patients with metastatic RCC were randomly assigned to pazopanib 800 mg per day for 10 weeks, a 2-week washout, and then sunitinib 50 mg per day (4 weeks on, 2 weeks off, 4 weeks on) for 10 weeks, or the reverse sequence…(ver más)